Friday Satellite Symposia
Research, Clinical trials, Clinical Research, Diseases, Immune Disorders, Treatment Considerations, Adverse Events
Grand Hall B
(Manchester Grand Hyatt San Diego)
Chair:
John O. Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Disclosures:
Mascarenhas: Disc: Consultancy; MorphoSys: Consultancy; Roche: Consultancy; Icahn School of Medicine at Mount Sinai: Current Employment; AbbVie: Consultancy, Research Funding; Merck: Consultancy; PharmaEssentia: Consultancy, Research Funding; Incyte Corporation: Consultancy, Speakers Bureau; Bristol Myers Squibb: Research Funding; Celgene: Consultancy, Other: Travel Support, Speakers Bureau; Kartos: Consultancy, Research Funding; CTI BioPharma/SOBI: Consultancy, Research Funding; Novartis: Consultancy, Other: Travel Support , Research Funding, Speakers Bureau; Pfizer: Research Funding; Sumitomo: Consultancy; GSK: Consultancy; Keros: Consultancy; Blueprint Medicines: Consultancy; Karyopharm: Consultancy; Geron: Consultancy, Research Funding; Ajax: Research Funding; NS Pharma: Research Funding; Ariad: Speakers Bureau; Astellas: Research Funding.
Speakers:
Mariana Castells, MD, PhD, Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital
,
Raajit Rampal, MD, PhD, ARRAY(0xe16de84)
and
Daniel J. DeAngelo, MD, Dana-Farber Cancer Institute
Disclosures:
Castells: Cogent Biosciences: Research Funding; Daiichi Sankyo: Consultancy; BluePrint: Research Funding. Rampal: CTI BioPharma: Consultancy; Zentalis: Consultancy, Research Funding; Ryvu: Research Funding; Kartos: Consultancy; Disc Medicine: Consultancy; Servier: Consultancy; Protagonist: Consultancy; AbbVie: Consultancy; Sumitomo Dainippon: Consultancy; Cogent: Consultancy; Karyopharm: Consultancy; Galecto: Consultancy; Jubilant: Consultancy; Constellation/MorphoSys: Consultancy, Research Funding; Sierra Oncology/GSK: Consultancy; Stemline Therapeutics: Consultancy, Research Funding; PharmaEssentia: Consultancy; Incyte Corporation: Consultancy, Research Funding; Blueprint: Consultancy; Celgene/BMS: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy; Promedior: Consultancy. DeAngelo: Takeda: Consultancy; Blueprint Medicines Corporation: Consultancy, Research Funding; Autolus: Consultancy; Amgen: Consultancy; Jazz: Consultancy; Forty-Seven: Consultancy; Novartis: Consultancy, Research Funding; Pfizer: Consultancy; Gilead: Consultancy; Servier: Consultancy; Abbvie: Research Funding; Glycomimetrics: Research Funding.
This symposium is CME-certified and will be presented live on Friday, December 6, 2024.
This activity is provided by HMP Education.
The live portion of this symposium will be presented as a live 2-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. This live educational activity will feature key experts in the field of MPNs/SM who will use an interactive, case-based approach to explore personalized care across the treatment continuum. This activity is designed to provide clinicians with the latest trial data, real-world evidence, and clinical practice guidelines to ensure timely and accurate diagnosis of MPNs/SM, an understanding of SM variants and genetic mutations, and utilization of a patient-centered treatment approach to optimize therapeutic selection and manage treatment-related adverse events.
Throughout this educational session, discussion spurred by patient cases, continuous clinical practice polling questions, and a live Q&A session will enhance learner engagement.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.